For over a year, the Pathways Home plan has been working to build the system of their 5-year plan. Earlier this week, they announced that 100 families have gone from homeless to housed since the ...
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half of 2026.
A phase 3 trial of lanifibranor, a pan-PPAR agonist, in patients with MASH and liver fibrosis is ongoing. But with the 96.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results